FIELD: medicine, immunology, pharmacy. SUBSTANCE: invention relates to functionally active modified superantigens. Invention presents conjugate exhibiting ability to activate immune system and pharmaceutical composition comprising indicated antigen. Conjugate shows the following formula: T-B- SA(m) where T means Fab-fragment of antibody directed to specific cancer antigen; B means covalent bridge bond and SA(m) means mutated staphylococcus enterotoxin E(SEE) where at least one amino acid residue at positions 20, 21, 24 and 27 in region A is replaced for amino acid at corresponding position of staphylococcus enterotoxin A(SEA). The proposed conjugate can be used as active component in treatment of different diseases being without by-side effects. EFFECT: valuable medicinal properties of conjugate. 5 cl, 2 tbl, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE TO STIMULATE IMMUNE RESPONSE AGAINST A TARGET CELL, METHOD TO TREAT MALIGNANT TUMORS IN MAMMALIANS | 1995 |
|
RU2183215C2 |
| NOVEL BIOTECHNOLOGICALLY CREATED SUPERANTIGEN FOR TREATING HUMANS | 2002 |
|
RU2307837C2 |
| ANTIBODY RAISED AGAINST TO HUMAN GASTROENTERIC TRACT EPITHELIAL TUMOR ANTIGEN RELATED WITH ALPHA-6,BETA-4-INTEGRIN | 2000 |
|
RU2266298C2 |
| SOLUBLE ANTIBODY CONJUGATE, METHOD OF TREATING ONCOLOGIC DISEASE, AND PHARMACEUTICAL COMPOSITION | 1991 |
|
RU2125889C1 |
| NEW ANTIBODY SHOWING SPECIFICITY TO MALIGNANT LARGE INTESTINE TUMOR | 2001 |
|
RU2268068C2 |
| AFFINE MOLECULE-OLIGONUCLEOTIDE CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2763554C2 |
| AFFINITY CONJUGATES - OLIGONUCLEOTIDE AND THEIR APPLICATIONS | 2016 |
|
RU2778754C2 |
| SINGLE-STRAND RECOMBINANT T-CELL RECEPTORS | 2003 |
|
RU2355703C2 |
| POLYMERIC CONJUGATE, A METHOD OF ITS SYNTHESIS AND A PHARMACEUTICAL COMPOSITION | 1993 |
|
RU2130462C1 |
| HUMANIZED ANTIBODIES AND THEIR UTILIZATION | 1994 |
|
RU2139934C1 |
